Adagio Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference

WALTHAM, Mass., Sep 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- WALTHAM, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc., /zigman2/quotes/228559245/composite ADGI +5.51% a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential, today announced that Tillman Gerngross, Ph.D., co-founder and chief executive officer of Adagio, will participate in a fireside chat during the Morgan Stanley 19th Annual Global Healthcare Conference on Wednesday, Sept. 15, 2021 at 1:15 p.m. ET.

The live webcast will be available in the investor section of the company's website at www.investors.adagiotx.com . The webcast will be archived for 60 days following the presentation.

About Adagio TherapeuticsAdagio /zigman2/quotes/228559245/composite ADGI +5.51% is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company's portfolio of antibodies has been optimized using Adimab's industry-leading antibody engineering capabilities and is designed to provide patients and clinicians with a powerful combination of potency, breadth, durable protection (via half-life extension), manufacturability and affordability. Adagio's portfolio of SARS-CoV-2 antibodies includes multiple, non-competing broadly neutralizing antibodies with distinct binding epitopes, led by ADG20. Adagio has secured manufacturing capacity for the production of ADG20 with third-party contract manufacturers through the completion of clinical trials and, if approved by regulatory authorities, through initial commercial launch. For more information, please visit www.adagiotx.com .

Contacts:
Media Contact:
Dan Budwick, 1AB
Dan@1abmedia.com

Investor Contact:
Monique Allaire, THRUST Strategic Communications
monique@thrustsc.com

COMTEX_392557712/2471/2021-09-01T06:30:04

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/228559245/composite